{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Estrogen+Receptor+Positive+HER2-+Breast+Cancer&page=2",
    "query": {
      "condition": "Advanced Estrogen Receptor Positive HER2- Breast Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Estrogen+Receptor+Positive+HER2-+Breast+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T09:12:35.468Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07029399",
      "title": "A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HR+ Breast Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "CCNE1 Amplified Advanced Solid Tumors",
        "HR+ HER2- Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKT5097 CDK2/CDK4 dual degrader",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NiKang Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 361,
      "start_date": "2025-03-25",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 18,
      "location_summary": "Duarte, California • La Jolla, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07029399"
    },
    {
      "nct_id": "NCT05306340",
      "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Giredestrant",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "LHRH Agonist",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone Mouth Rinse",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 373,
      "start_date": "2022-08-03",
      "completion_date": "2026-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 55,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05306340"
    },
    {
      "nct_id": "NCT02422615",
      "title": "Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 726,
      "start_date": "2015-06-09",
      "completion_date": "2023-01-11",
      "has_results": true,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422615"
    },
    {
      "nct_id": "NCT00073528",
      "title": "Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1286,
      "start_date": "2003-12-09",
      "completion_date": "2018-03-22",
      "has_results": true,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 84,
      "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 78 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073528"
    },
    {
      "nct_id": "NCT01697293",
      "title": "PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Recurrent Breast Carcinoma",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Triciribine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Prescient Therapeutics, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-01",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • The Bronx, New York",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01697293"
    },
    {
      "nct_id": "NCT05187832",
      "title": "A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AND019 PO QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kind Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 61,
      "start_date": "2022-10-05",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05187832"
    },
    {
      "nct_id": "NCT02152943",
      "title": "Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Estrogen Receptor Positive",
        "HER2/Neu Positive",
        "Postmenopausal",
        "Premenopausal",
        "Progesterone Receptor Positive",
        "Recurrent Breast Carcinoma",
        "Refractory Breast Carcinoma",
        "Refractory Hormone Receptor Positive Breast Carcinoma",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-07-17",
      "completion_date": "2020-12-14",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 5,
      "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Nassau Bay",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02152943"
    },
    {
      "nct_id": "NCT05054374",
      "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Stage IV",
        "HER2-negative Breast Cancer",
        "Solid Carcinoma",
        "MEK1 Gene Mutation",
        "MEK2 Gene Mutation",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Mirdametinib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-14",
      "completion_date": "2023-10-26",
      "has_results": true,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 4,
      "location_summary": "Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more",
      "locations": [
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05054374"
    },
    {
      "nct_id": "NCT03725436",
      "title": "ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Metastatic Malignant Solid Neoplasm",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Recurrent Breast Carcinoma",
        "TP53 wt Allele",
        "Unresectable Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "MDM2/MDMX Inhibitor ALRN-6924",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2019-01-24",
      "completion_date": "2026-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03725436"
    },
    {
      "nct_id": "NCT06993844",
      "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ETX-636 dose escalation",
          "type": "DRUG"
        },
        {
          "name": "ETX-636 dose escalation in combination with fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "ETX-636 dose expansion in combination with fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ensem Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2025-06-10",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-06-27T09:12:35.468Z",
      "location_count": 10,
      "location_summary": "Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06993844"
    }
  ]
}